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Rolf Stahel reported on behalf of the Swiss Group for
Clinical Cancer Research (SAKK) the final results of the
multicenter phase 2 trial on neoadjuvant chemotherapy, fol-
lowed by extrapeural pneumonectomy (EEP) in malignant
pleural mesothelioma (MPM).1 Eligible patients with perfor-
mance status 0-2, all histological subtypes, stage T1-3, N0-2
M0 were treated with three cycles of cisplatin-gemcitabine at
standard doses. EPP was performed, followed by postopera-
tive radiotherapy on high-risk or obviously incompletely
resected areas. Quality of life analysis was included. Of the
63 included patients, two had progression on chemotherapy,
58 completed chemotherapy, 54 underwent surgery, 13 were
considered inoperable, 45 underwent EPP, 37 were consid-
ered completely resected, one died postoperatively, 36 pa-
tients started radiotherapy (median 8 weeks after the resec-
tion), and 38 patients had recurrent disease; however, its
pattern was not presented. Median overall survival was 19.8
months (intention to treat) versus 23 months for the 45
patients who underwent resection. Median time to recurrence
was 13.8 months. Quality of life was not severely impaired
and reversible 3 months after surgery. The authors conclude
that these multicenter results confirm their earlier phase 2 single-
center data and warrant further prospective investigation of this
combined approach in MPM. They are currently conducting a
randomized trial, allocating patients after induction chemother-
apy and EPP to postoperative radiotherapy or not.
Jacek Jassem reported the results of an international
randomized trial comparing pemetrexed and best support-
ive care (BSC) among previously treated patients with
advanced MPM.1 Eligible patients had to be pretreated
with one previous line of chemotherapy excluding pem-
etrexed; randomization was between best supportive care
(not defined) and pemetrexed 500 mg/m2 every 3 weeks
and vitamins till progression. Third-line therapy, including
pemetrexed, was allowed thereafter. The investigators ran-
domized 252 patients: 123 to pemetrexed and 120 to BSC.
Patient characteristics were well balanced, but data on
duration of best response to first-line therapy were lacking.
The median number of cycles given was five, and pem-
etrexed was well tolerated (7% grade 3 or 4 neutropenia
and 6% anemia). Disease stabilization (OR  SD) oc-
curred in 59% of patients, compared with 19% in the BSC
arm. A significant increase was noted in the median time-
to-progression (median, 3.6 versus 1.5 months; p  0.015)
but not for overall survival (8.6 versus 9.7 months; p 
0.7). This was thought to be the result of second-line
treatment, which was given to 52% of patients in the BSC
arm, including pemetrexed in 18% of these. This assump-
tion was strengthened by two unplanned exploratory anal-
yses, which showed a significant improvement in survival
for various pemetrexed-treated subgroups of the study
population. The authors concluded that single-agent pem-
etrexed was likely to improve outcome as second-line
treatment for pretreated patients.
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